Impact of the 1997 Canadian guidelines on the conduct of Canadian-based economic evaluations in the published literature

Value in Health

Volumn 13, Issue 2, 2010, Pages 328-334

  Lim, Morgan E ^a,b   Bowen, James M ^a,b   O'Reilly, Daria ^a,b   McCarron, C Elizabeth ^a,b   Blackhouse, Gord ^a,b   Hopkins, Robert ^a,b   Goeree, Ron ^a,b   Tarride, Jean Eric ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Economic evaluation; Guideline; Health technology assessment

Indexed keywords

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CANADA; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; FUNDING; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; STANDARD;

EID: 77149168737     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00613.x     Document Type: Article

References (15)

1. Laupacis A. Economic evaluations in the Canadian Common Drug review. Pharmacoeconomics 2006 24 : 1157 1162.
2. Rocchi A, Menon D, Verma S, et al. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health 2008 11 : 771 783.
3. Australian Commonwealth Department of Health Housing, Community Services. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee, Including Submissions Involving Economic Analyses. Canberra : Australian Government Publishing Service, 1992.
4. International Society for Pharmacoecononomics and Outcomes Research. Pharmacoeconomic Guidelines Around the World. 2008 Available from: http://www.ispor.org/peguidelines/index.asp [Accessed July 11, 2008 J, Berggren F, Andersson F. Health economic guidelines - similarities, differences and some implications. Value Health 2001 4 : 225 250.
5. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for Economic Evaluation of Pharmaceuticals. Ottawa : CCOHTA, 1994.
6. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for Economic Evaluation of Pharmaceuticals (2nd ed Ottawa : CCOHTA, 1997.
7. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies (3rd ed Ottawa : CADTH, 2006.
8. Baladi JF, Menon D, Otten N. Use of economic evaluation guidelines: 2 years' experience in Canada. Health Econ 1998 7 : 221 227.
9. Anis AH, Rahman T, Schechter MT. Using pharmacoeconomic analysis to make drug insurance coverage decisions. Pharmacoeconomics 1998 13 (1 Pt 119 126.
10. Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions. So much for guidelines. Pharmacoeconomics 2000 18 : 55 62.
11. Johannesson M. The willingness to pay for health changes, the human-capital approach and the external costs. Health Policy 1996 36 : 231 244.
12. Koopmanschap MA, Rutten FFH, van Ivenveld BM, van Roijen L. The friction cost method for measuring indirect cost of disease. J Health Econ 1995 14 : 171 189.
13. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998 13 : 1 7.
14. Tarride J-E, McCarron CE, Lim M, et al. Economic evaluations conducted by Canadian health technology assessment agencies: where do we stand? Int J Technol Assess Health Care 2008 24 : 437 444.
15. Hoffman C, von der Schulenburg JMG. The influence of economic evaluation studies on decision making. A European survey. Health Policy 2000 52 : 179 192.